Thanks, Ike, for all your incredibly hard work. Unlike others I think we learned a lot from the company’s responses to our questions. We learned that they actually started the countdown to Data lock on November 19 and that the work toward data lock is ongoing. We also learned that they are planning a response to the short attack. Most importantly, Les talked to you about multiple ways they could move forward and how they may use different avenues in different countries. They also talked about randomization though I hope meeting goers question them about that one. To be off by 17 in the SOC but none in treatment seems a little odd. On that note I just want to tell you that I will not be at the meeting because of an ongoing injury to my leg, which I expect to be healed by now. But it’s continuing to plague me and I’m not comfortable going into the city and walking around on my own.
I hope you or someone else at the meeting will ask them about adjudication of PFS, whether it has started and been completed and whether it looks promising for extending medium PFS. I’m also interested in what’s happening with Advent, and it would be nice if Linda can address why she sold 3.5 million shares and whether she still owns 29 million shares and plans to keep them. Finally, can Linda tell us if she believes her new investment, INmune, might work with DCVax and how?
AI
Market Data 
Markets 
